Community-acquired pneumonia briefly about the main. What is important to know to the physician. Based on the materials of the Russian National Congress «Man and Drug» and the III Pulmonology Summit
https://doi.org/10.26295/OS.2019.89.41.013
Abstract
Recently more and more cases of viral community-acquired pneumonia have been recorded. Laboratory markers (C-reactive protein, procalcitonin) can help diagnose this disease and determine its prognosis. When choosing an antimicrobial drug, data on antibiotic resistance, the presence of concomitant diseases, previous antibiotic therapy should be taken into consideration. An effective measure for the prevention of community-acquired pneumonia is vaccination against pneumococcus and influenza.
References
1. Jain S., Self W. H., Wunderink R. G. et al. Community-Acquired Pneumonia Requiring Hospitalization // N Engl J. Med. 2015; 373: 2382.
2. Wu X., Wang Q., Wang M. S. et al. Incidence of respiratory viral infections detected by PCR and real-time PCR in adult patients with community-acquired pneumonia: a meta-analysis // Respiration. 2015; 89: 343-352.
3. Alimi Y., Lim W. S., Lansbury L. et al. Systematic review of respiratory viral pathogens identified in adults with community-acquired pneumonia in Europe // J Clin Virol. 2017; 95: 26-35.
4. Piralla A., Rovida F., Girello A. et al. Frequency of respiratory virus infections and next-generation analysis of influenza A/H1N1pdm09 dynamics in the lower respiratory tract of patients admitted to the ICU // PloS One. 2017; 12: e0178926.
5. Shah R. D., Wunderink R. G. Viral Pneumonia and Acute Respiratory Distress Syndrome // Clin Chest Med. 2017; 38: 113-125.
6. Scheltema N. M., Gentile A., Lucion F. et al. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series // Lancet Glob Health. 2017; 5: e984-991.
7. Cherazard R., Epstein M., Doan T. L. et al. Antimicrobial Resistant Streptococcus pneumoniae: Prevalence, Mechanisms, and Clinical Implications // Am J Ther. 2017; 24 (3): e361-e369.
8. Torumkuney D., Mayanskiy N., Edelstein M. et al. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Russia // J Antimicrob Chemother. 2018; 73 (suppl. 5): v. 14-21.
9. Restrepo M. I., Babu B. L., Reyes L. F. et al. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients // Eur Respir J. 2018; 52.
10. Long L., Zhao H. T., Zhang Z. Y. et al. Lung ultrasound for the diagnosis of pneumonia in adults: A meta-analysis // Medicine (Baltimore). 2017; 96 (3): e5713.
11. Bellew S., Grijalva C. G., Williams D. J. et al. Pneumococcal and Legionella Urinary Antigen Tests in Community-acquired Pneumonia: Prospective Evaluation of Indications for Testing // Clinical Infectious Diseases. 2019; 68 (12): 2026-2033.
12. Schuetz P., Chiappa V., Briel M., Greenwald J. L. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms // Arch Intern Med. 2011; 171(15): 1322-1331.
13. Huang D. T., Yealy D. M., Filbin M. R. et al. Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection // N Engl J Med. 2018; 379: 236-249.
14. Рачина С. А., Синопальников А. И. Клинические рекомендации по внебольничной пневмонии у взрослых: что нас ждет в 2019 г // Практическая пульмонология. 2018; 3: 8-13.
15. Федеральные клинические рекомендации. Внебольничная пневмония. 2018.
Review
For citations:
Evsutina Yu.V. Community-acquired pneumonia briefly about the main. What is important to know to the physician. Based on the materials of the Russian National Congress «Man and Drug» and the III Pulmonology Summit. Lechaschi Vrach. 2019;(11):56-59. (In Russ.) https://doi.org/10.26295/OS.2019.89.41.013
Views:
258
JATS XML
Email this article 
